GRFS vs RGEN

GRFS presents a classic 'value trap' profile: strong deterministic health (Piotroski F-Score 7/9) and deep valuation discounts (Price < Graham Number < Intrinsic Value), yet it suffers from severe market rejection. While the stock trades at a significant discount to its Graham Number of $11.36 and Intrinsic Value of $18.88, this is offset by a 0/100 technical trend and a dismal earnings track record with 0 beats in the last 4 quarters. The disconnect between strong operational health scores and poor price performance suggests systemic risks or lack of catalyst for a reversal.

RGEN exhibits a critical disconnect between its market valuation and fundamental performance, characterized by a stable but mediocre Piotroski F-Score of 4/9 and a current price ($118.29) that vastly exceeds its Graham Number ($26.9) and Intrinsic Value ($6.02). While the balance sheet is exceptionally liquid with a Current Ratio of 8.37 and low debt, the company is suffering from a severe earnings collapse (-47.7% YoY EPS growth) and a negligible ROE of 2.40%. Despite bullish analyst targets, the combination of a PEG ratio of 8.23, bearish insider selling, and a negative 5-year price trend suggests the stock is significantly overvalued.